Organovo announced that its data on the activity of FXR314 in its proprietary 3D human tissue models of Crohn’s disease and ulcerative colitis will be presented at the Crohn’s and Colitis Congress to be held January 25-27, 2024 in Las Vegas, Nevada. “We initially identified a strong benefit of FXR agonism in IBD using our internal 3D models, then moved towards development of what we believe to be a best-in-class FXR agonist, FXR314, to treat IBD,” said Keith Murphy, Organovo’s Executive Chairman. “Our 3D human tissue models rely on primary cells isolated from individual donors with disease, and we believe our findings to constitute a translational research “gold standard” far superior and complimentary to preclinical animal models alone. FXR314 shows excellent results in standard preclinical models as well. In this presentation, data from our 3D models of IBD, especially the effect of FXR314 on multiple endpoints of IBD including epithelial barrier function and fibrosis in a wide set of Crohn’s disease and ulcerative colitis donors, will be shown.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ONVO:
- Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
- Organovo provides timing for release of FXR314 Phase 2 NASH results
- Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
- CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan